Skip to content
Open access

Preclinical Safety Evaluation of a Replication-Defective Canine Adenovirus Type 2 Vector-Based SARS-CoV-2 Vaccine Candidate in Murine Models

Jul 2026 · Vaccines · Vol 14, pp. 647 · 0 citations · 40 references
Medicine

TL;DR

It is demonstrated that the CAV-2 vector exhibits a favourable safety profile in murine models when used as a vaccine delivery platform, supporting its translational potential as an alternative adenoviral vector-based vaccine platform.

Abstract

Background: Adenoviral vectors are widely used in vaccine development; however, pre-existing immunity to common human adenovirus serotypes can limit their effectiveness. Canine adenovirus type 2 (CAV-2) is a non-human adenovirus with low seroprevalence in humans, making it a suitable alternative vector. Despite its promise, comprehensive preclinical safety data for CAV-2 vector-based vaccine platforms remain limited. In this study, we evaluated the safety profile of a replication-defective CAV-2 vector expressing the Omicron BA.4 SARS-CoV-2 spike immunogen in BALB/c mouse models. Methods: The SARS-CoV-2 CAV-2 vector-based vaccine was expressed and propagated in AD293 cells. The mice received intramuscular prime-boost immunisations with low (1 × 106 PFU), moderate (0.5 × 1010 PFU), or high (1 × 1010 PFU) vaccine doses, alongside empty CAV-2 vector and physiological buffer control groups, and were monitored longitudinally up to Day 72. The mice were clinically assessed at days 0, 7, 21, 42, and 72 for any deviations from normal conditions in comparison to the control groups. Biochemical analyses were performed to evaluate liver and kidney function, as well as any tissue injury due to the vaccine candidate. Hematological parameters were assessed by conducting complete blood counts. Body temperature and weight changes were also monitored as an indicator of systemic toxicity. Results: The biochemical and haematological parameters remained within physiological reference ranges across all dose groups and timepoints, with no dose-related deviations, indicating that the vaccine candidate did not show evidence of hepatotoxicity, nephrotoxicity, tissue or haematological toxicity. Body temperatures remained within normal physiological ranges following both prime and booster immunisations, and body weights increased normally across all groups as the animals grew throughout the study period without any abnormal weight gain or loss. Conclusions: These results suggest that the replication-defective CAV-2-vectored SARS-CoV-2 vaccine candidate was well tolerated and did not demonstrate evidence of systemic toxicity under the conditions tested. These findings demonstrate that the CAV-2 vector exhibits a favourable safety profile in murine models when used as a vaccine delivery platform, supporting its translational potential as an alternative adenoviral vector-based vaccine platform. Further studies incorporating additional safety endpoints, including histopathological, vector persistence and shedding evaluation, are warranted to support continued development of the platform.

Read PDF

Similar papers

Open access Sep 2026

Chimeric SARS-CoV-2 vaccine vectors stably incorporating the functional glycoprotein of VSV

Stable genetic incorporation and display of a functional heterologous glycoprotein into a SARS-CoV-2 virion are demonstrated, supporting use of the ΔE SARS-CoV-2 backbone as a potential platform for viral vector engineering and heterologous antigen delivery.

E. Kipfer, Jacob Schön, Mohamed Chami et al. · 0 citations
Open access Sep 2026

Establishment of a CD46 and desmoglein-2 expressing mouse model for human adenovirus type 55 vaccine evaluation.

Human adenovirus type 55 (HAdV-55) is an emerging respiratory pathogen associated with severe pneumonia, for which no licensed vaccines are currently available. The lack of physiologically relevant small-animal models has limited preclinical evaluation of vaccine candidates. In this study, we generated a transgenic mou...

Jung-Ah Choi, Eunji Yang, Shing Young Noh et al. · 0 citations
Open access Oct 2026

An adenovirus-based mucosal vaccine induces cross-neutralizing antibodies and protects against lethal H5N1 infection in ferrets

Second-generation VXA-H5–02 is a promising vaccine candidate capable of inducing systemic and mucosal immunity, offering broad protection against HPAI, and significantly reduced illness, viral burden, and shedding.

Becca A. Flitter, Ka-Yan Tam, Laura J. Showalter et al. · 0 citations
Open access Aug 2026

Long-term immunity and protection against SARS-CoV-2 XBB.1.5 following homologous and heterologous mRNA and MVA vaccination

Although mRNA-based COVID-19 vaccines have demonstrated high efficacy, their widespread global use remains constrained by high production costs and cold-chain requirements. Modified vaccinia virus Ankara (MVA) is a highly attenuated and thermostable viral vector with low production costs, potent immunogenicity, and str...

Patricia Pérez, G. Esteso, Isabel García-García et al. · 0 citations
Aug 2026

A novel candidate vaccine virus derived from Japan's first mammalian case of clade 2.3.4.4b A/H5N1 highly pathogenic avian influenza virus.

Overall, NIID-002 fulfills the key requirements for the pandemic preparedness of CVV, combining reduced pathogenicity, broad antigenic reactivity, and adequate production efficiency, which underscores the continued need for surveillance and refinement of influenza vaccine strategies to address evolving viral threats.

Yasushi Suzuki, Tomoko Arita, Masayuki Shirakura et al. · 0 citations
Open access Sep 2026

Development and evaluation of bovine adenovirus vector-based avian influenza vaccine efficacy in poultry

Overall, the BAdV-(H5N1)HA+ (H7N9)NP vaccine elicited AIV-specific humoral, mucosal, and cellular immune responses and was associated with a reduced percentage of virus-isolation-positive tracheal samples, particularly following IO administration, compared with the other vaccination routes.

Shekoni Olaitan Comfort, Ekramy E. Sayedahmed, Wen-Chien Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.